pT2-3N0M0期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展

doi:10.3760/cma.j.cn371439-20240528-00006

摘要/Abstract

摘要：

pT_2-3N₀M₀期胸段食管鳞状细胞癌患者虽然分期较早，但术后局部复发及远处转移率较高，导致此类患者5年生存率较低，并且目前此类患者的新辅助治疗仍处在研究阶段，术后是否予以辅助放化疗仍存在争议。此外，pT_2-3N₀M₀期胸段食管鳞状细胞癌患者的预后影响因素尚未明确，复发与转移的原因尚不清楚。因此，明确治疗策略及探索预后影响因素对提高此类患者的生存率有重要意义，有望为pT_2-3N₀M₀期胸段食管鳞状细胞癌患者改善预后、提高生存率提供新方向。

关键词: 食道鳞癌, 肿瘤治疗方案, 预后

Abstract:

Although patients with stage pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma are staged earlier， their postoperative local recurrence and distant metastasis rates are higher， resulting in a low five-year survival rate of such patients. The current neoadjuvant treatment for such patients is still in the research stage， and whether to give adjuvant radiotherapy and chemotherapy after surgery is still controversial. In addition， the prognostic factors of patients with pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma have not yet been clarified， and the causes of recurrence and metastasis are not yet clear. Therefore， it is of great significance to clarify treatment strategies and explore the impact of prognostic factors on improving the survival rate of such patients， which is expected to provide new directions for improving the prognosis and survival rate of patients with pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma.

Key words: Esophageal squamous cell carcinoma, Antineoplastic protocols, Prognosis

余洋, 唐仕敏, 杨露, 李娜. pT_2-3N₀M₀期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展[J]. 国际肿瘤学杂志, 2025, 52(1): 43-47.

Yu Yang, Tang Shimin, Yang Lu, Li Na. Research progress in treatment strategies and prognostic factors for stage pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(1): 43-47.

参考文献 34

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI:10.3760/cma.j.cn112152-20240119-00035.
[3]	Deng W, Yang J, Ni W, et al. Postoperative radiotherapy in pathological T_2-3N₀M₀ thoracic esophageal squamous cell carcinoma: interim report of a prospective, phase Ⅲ, randomized controlled study[J]. Oncologist, 2020, 25(4): e701-e708. DOI: 10.1634/theoncologist.2019-0276.
[4]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2023[M]. 北京: 人民卫生出版社, 2023.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2023年版)[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20. DOI: 10.3760/cma.j.cn371439-20231221-00001.
[6]	National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Esophageal and Esophagogastric Junction Cancers, Version 3. 2024[EB/OL]. (2024-04-26) [2024-05-21]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[7]	de Groot EM, Goense L, Kingma BF, et al. Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update[J]. Dis Esophagus, 2023, 36(7): doac099. DOI: 10.1093/dote/doac099.
[8]	中华人民共和国国家卫生健康委员会医政医管局. 食管癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(10): 1247-1268. DOI: 10.3760/cma.j.cn115610-20220726-00433.
[9]	Yoshida N, Yamamoto H, Baba H, et al. Can minimally invasive esophagectomy replace open esophagectomy for esophageal cancer? Latest analysis of 24,233 esophagectomies from the Japanese National Clinical Database[J]. Ann Surg, 2020, 272(1): 118-124. DOI: 10.1097/SLA.0000000000003222. pmid: 30720501
[10]	Wang BY, Lin CH, Wu SC, et al. Survival comparison between open and thoracoscopic upfront esophagectomy in patients with esophageal squamous cell carcinoma[J]. Ann Surg, 2023, 277(1): e53-e60. DOI: 10.1097/SLA.0000000000004968.
[11]	中国抗癌协会食管癌专业委员会. 机器人辅助食管切除术中国临床专家共识(2023版)[J]. 中华胸部外科电子杂志, 2024, 11(1): 1-15. DOI: 10.3877/cma.j.issn.2095-8773.2024.01.01.
[12]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[13]	Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial[J]. Ann Oncol, 2023, 34(2): 163-172. DOI: 10.1016/j.annonc.2022.10.508.
[14]	Wakita A, Motoyama S, Sato Y, et al. Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T₃ thoracic esophageal cancer[J]. Ann Gastroenterol Surg, 2023, 7(6): 904-912. DOI: 10.1002/ags3.12706.
[15]	Song C, Zhu S, Xu J, et al. Patterns of failure and long-term outcome of postoperative radiotherapy on the survival of patients with pathological T₃N₀M₀ esophageal cancer[J]. Front Surg, 2022, 9: 959568. DOI: 10.3389/fsurg.2022.959568.
[16]	Yang H, Li X, Yang W. Advances in targeted therapy and immunotherapy for esophageal cancer[J]. Chin Med J (Engl), 2023, 136(16): 1910-1922. DOI: 10.1097/CM9.0000000000002768.
[17]	Ge F, Huo Z, Cai X, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis[J]. JAMA Netw Open, 2022, 5(11): e2239778. DOI: 10.1001/jamanetworkopen.2022.39778.
[18]	Asakura T, Hashimoto T, Ando T, et al. Degree of differentiation of esophageal squamous cell carcinoma and micrometastasis to lymph nodes[J]. Juntendo Iji Zasshi, 2022, 68(4): 363-368. DOI: 10.14789/jmj.JMJ21-0041-OA. pmid: 39021430
[19]	Feng W, Qi Z, Qiu R, et al. Risk factors for tumor recurrence in patients with pT₃N₀M₀ thoracic esophageal squamous cell carcinoma after esophagectomy[J]. J Int Med Res, 2020, 48(12): 300060520 977403. DOI: 10.1177/0300060520977403.
[20]	Kim HE, Park SY, Kim H, et al. Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma[J]. Thorac Cancer, 2021, 12(10): 1605-1612. DOI: 10.1111/1759-7714.13960. pmid: 33811752
[21]	Guo YN, Tian DP, Gong QY, et al. Perineural invasion is a better prognostic indicator than lymphovascular invasion and a potential adjuvant therapy indicator for pN₀M₀ esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2020, 27(11): 4371-4381. DOI: 10.1245/s10434-020-08667-4.
[22]	Haneda R, Kikuchi H, Nagakura Y, et al. Development and validation of the optimal circumferential resection margin in pathological T₃ esophageal cancer: a multicenter retrospective study[J]. Ann Surg Oncol, 2022, 29: 4452-4461. DOI: 10.1245/s10434-022-11491-7.
[23]	Okada NY, Fujii S, Fujita TK, et al. The prognostic significance of the positive circumferential resection margin in pathologic T₃ squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy[J]. Surgery, 2016, 159(2): 441-450. DOI: 10.1016/j.surg.2015.06.044.
[24]	王崇礼, 曹富民. 食管鳞癌环周切缘的临床意义分析[J]. 中华胸心血管外科杂志, 2022, 38(1): 5-12. DOI: 10.3760/cma.j.cn112434-20201218-00541.
[25]	Kang M, Wang Y, Yang M, et al. Prognostic nomogram and risk factors for predicting survival in patients with pT₂N₀M₀ esophageal squamous carcinoma[J]. Sci Rep, 2023, 13(1): 4931. DOI: 10.1038/s41598-023-32171-w. pmid: 36967413
[26]	Li J, Mei X, Sun D, et al. A nutrition and inflammation-related nomogram to predict overall survival in surgically resected esophageal squamous cell carcinoma (ESCC) patients[J]. Nutr Cancer, 2022, 74(5): 1625-1635. DOI: 10.1080/01635581.2021.1957131.
[27]	中国抗癌协会肿瘤放射治疗专业委员会, 中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会. 食管癌放疗联合免疫治疗专家共识(2023年版)[J]. 中华放射医学与防护杂志, 2023, 43(8): 575-587. DOI: 10.3760/cma.j.cn112271-20230626-00207.
[28]	Kato K, Ito Y, Daiko H, et al. A randomized controlled phase Ⅲ trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study[J]. J Clin Oncol, 2022, 40(4_suppl): 238-238. DOI: 10.1200/JCO.2022.40.4_suppl.238.
[29]	Wang Q, Peng L, Li T, et al. Postoperative chemotherapy for thoracic pathological T₃N₀M₀ esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2020, 27(5): 1488-1495. DOI: 10.1245/s10434-019-08112-1.
[30]	Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase Ⅱ trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(3): e004291. DOI: 10.1136/jitc-2021-004291.
[31]	Kang K, Wu J, Mao Y, et al. Role of SLC44A3-AS1 enhancer RNA in esophageal cancer prognosis[J]. J Coll Physicians Surg Pak, 2023, 33(9): 964-971. DOI: 10.29271/jcpsp.2023.09.964. pmid: 37691355
[32]	Zhou L, Gan L, Liu Z. Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma[J]. Medicine (Baltimore), 2023, 102(34): e34677. DOI: 10.1097/MD.0000000000034677.
[33]	Song WP, Wang SY, Zhou SC, et al. Prognostic and clinicopathological value of twist expression in esophageal cancer: a meta-analysis[J]. World J Gastrointest Oncol, 2022, 14(9): 1874-1886. DOI: 10.4251/wjgo.v14.i9.1874.
[34]	向光宇, 李家贺, 季刚, 等. 单细胞RNA测序技术在食管鳞状细胞癌辅助诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(12): 745-748. DOI: 10.3760/cma.j.cn371439-20220816-00146.

pT_2-3N₀M₀期胸段食管鳞状细胞癌治疗策略及预后影响因素研究进展

Research progress in treatment strategies and prognostic factors for stage pT_2-3N₀M₀ thoracic esophageal squamous cell carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价

[1]	叶永英, 邹艳, 陈天明, 吴伟莉. 时钟基因Period家族在头颈鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2025, 52(2): 113-118.
[2]	陈丹蕾, 邓隽军, 李淼. 循环肿瘤细胞在肺癌中的临床应用进展[J]. 国际肿瘤学杂志, 2025, 52(2): 119-123.
[3]	马培晗, 张灵敏, 李茜, 路宁, 温华, 张明鑫. ALKBH5对食管鳞状细胞癌恶性生物学行为的影响及相关机制研究[J]. 国际肿瘤学杂志, 2025, 52(2): 79-88.
[4]	姬海涛, 王延峰, 刘永成, 郝楠. 基于生物信息学分析DHCR7在胃癌中的表达及临床意义[J]. 国际肿瘤学杂志, 2025, 52(2): 94-100.
[5]	吴晓维, 胡格, 陈莉, 钱晓涛, 崔相利, 朱凤琴. 放疗前肿瘤最大径、外周血NLR对食管鳞状细胞癌患者放疗后发生食管瘘的预测价值[J]. 国际肿瘤学杂志, 2025, 52(1): 38-42.
[6]	袁胜芳, 任婕, 林卫佳, 姬泽萱, 张长洪, 王布. EGFR共突变状态对晚期肺腺癌患者预后的价值研究[J]. 国际肿瘤学杂志, 2024, 51(9): 556-562.
[7]	倪国英, 黄骞, 梁洪享, 杨志勇, 丁颖丽. 晚期非小细胞肺癌患者血清miR-499、miR-362水平变化及与预后的关系分析[J]. 国际肿瘤学杂志, 2024, 51(8): 487-492.
[8]	孟珂心, 陆海军. 口腔菌群：口腔鳞状细胞癌诊断和预后的生物标志物[J]. 国际肿瘤学杂志, 2024, 51(8): 515-519.
[9]	韩艺, 张同梅, 齐菲, 张泳. 肺大细胞神经内分泌癌临床分子诊断和治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(7): 468-473.
[10]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[11]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[12]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[15]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.